LEXICON PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.8M | $31.1M | $1.2M | $139.0K | $298.0K | $24.0M | $322.1M | $63.2M |
| Cost of Revenue | $274.0K | $616.0K | $85.0K | $0 | $0 | $1.9M | $3.2M | $2.5M |
| Gross Profit | $49.5M | $30.5M | $1.1M | $139.0K | $298.0K | $22.1M | $318.8M | $60.7M |
| Gross Margin | 99.4% | 98.0% | 92.9% | 100.0% | 100.0% | 92.0% | 99.0% | 96.1% |
| Operating Expenses | ||||||||
| Research & Development | $61.1M | $84.5M | $58.9M | $52.8M | $55.0M | $153.6M | $91.9M | $100.2M |
| SG&A Expense | $37.3M | $143.1M | $114.0M | $48.1M | $32.3M | $47.2M | $56.8M | $63.8M |
| Operating Income | $-48.9M | $-197.1M | $-171.8M | $-100.8M | $-87.1M | $-47.8M | $141.4M | $-103.3M |
| Operating Margin | -98.2% | -634.2% | -14,265.0% | -72,489.2% | -29,224.8% | -199.2% | 43.9% | -163.4% |
| Interest Expense | — | — | — | $2.8M | $802.0K | $14.5M | $20.7M | $20.8M |
| Pretax Income | — | — | — | — | $-87.8M | $-58.6M | $124.1M | $-120.5M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | — | — | — |
| Net Income | $-50.3M | $-200.4M | $-177.1M | $-101.9M | $-87.8M | $-58.6M | $130.1M | $-120.5M |
| Net Margin | -101.1% | -644.8% | -14,710.9% | -73,341.0% | -29,449.0% | -244.1% | 40.4% | -190.7% |
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 |
| Shares Outstanding (Basic) | 363.1M | 320.0M | 221.1M | 165.7M | 145.7M | — | — | — |
| Shares Outstanding (Diluted) | 363.1M | 320.0M | 221.1M | 165.7M | 145.7M | 110.8M | 116.7M | 105.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |